Compare OCSL & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCSL | EYPT |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2007 | 2005 |
| Metric | OCSL | EYPT |
|---|---|---|
| Price | $13.12 | $14.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $13.10 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 992.9K | 780.9K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 12.59% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.31 | $3,115.57 |
| P/E Ratio | $211.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.63 | $5.44 |
| 52 Week High | $14.90 | $19.11 |
| Indicator | OCSL | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 76.29 | 57.87 |
| Support Level | $12.50 | $14.50 |
| Resistance Level | $13.89 | $18.99 |
| Average True Range (ATR) | 0.30 | 0.65 |
| MACD | 0.19 | 0.26 |
| Stochastic Oscillator | 88.89 | 88.92 |
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.